Released Aug 9, 2019, after the close
10-Q filed Aug 12, 2019, 43 days after period end · 0001493152-19-012078
Q2 2019 · 10-Q
Revenue$5.23M$5.23M −7.5% vs Q2 2018+8.2% vs Q1 2019
Net Income-$90.00K-$90.00K N/M vs Q2 2018N/M vs Q1 2019
EPS Diluted-$0.03-$0.03 N/M vs Q2 2018N/M vs Q1 2019
Operating Income-$2,000N/M
Operating Cash Flowderived$559,000+55.7%
Free Cash Flowderived$521,000+110.1%
Margins · derived
Operating margin-0.0%+0.4 pt vs Q2 2018
Net margin-1.7%+0.5 pt vs Q2 2018
What the release said
The release
Same quarter
| Metric | Q2 2019 | Q2 2018 | Q2 2017 | Q2 2016 |
|---|---|---|---|---|
| Revenue | $5.23M | $5.65M | $5.55M | $5.41M |
| Net Income | -$90.00K | -$124.00K | -$164.00K | -$850.00K |
| EPS Diluted | -$0.03 | -$0.05 | -$0.07 | -$0.46 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR